TAK-003 Dengue Vaccine Efficacy and Safety: A Systematic Literature Review Using PRISMA
DOI:
https://doi.org/10.47134/inhis.v5i1.164Keywords:
TAK-003, Dengue Vaccine, Efektivitas, Keamanan, PRISMAAbstract
Background: Dengue is a global public health problem with a high disease burden in both endemic and non-endemic regions. Although dengue vaccines have been developed, evidence regarding the efficacy and safety of the TAK-003 vaccine remains fragmented, with variations across serotypes, age groups, baseline serostatus, and study designs. Objective: This study aims to analyze and synthesize scientific evidence on the efficacy and safety of the tetravalent dengue vaccine TAK-003 based on clinical trial data and real-world evidence. Methods: A Systematic Literature Review was conducted in January 2025 in accordance with PRISMA guidelines. Literature searches were performed in the ScienceDirect, PubMed, ProQuest, and ClinicalKey databases, yielding a total of 1,011 initial records. After duplicate removal, title and abstract screening, and full-text eligibility assessment, studies were included if they: (1) explicitly investigated TAK-003, (2) reported outcomes related to efficacy, immunogenicity, and/or safety, (3) employed clinical trial, observational, or post-marketing surveillance designs, and (4) were available as full-text articles in English. Non-empirical studies, animal studies, commentaries, and narrative reviews were excluded. Results: Five high-quality articles from Scopus Q1 journals met the inclusion criteria. The thematic analysis identified five main themes: the safety and immunogenicity of TAK-003 when co-administered with other vaccines, manufacturing consistency with stable immune responses, long-term effectiveness in preventing dengue infection and hospitalization for up to 4.5 years, tetravalent protection against all four dengue serotypes, and a favorable safety profile based on post-marketing data, with most adverse events being mild. Conclusion: The TAK-003 vaccine demonstrates favorable efficacy and safety profiles in both clinical trials and real-world settings. Although variability in effectiveness across serotypes and age groups persists, the available evidence supports TAK-003 as a promising strategy for dengue prevention.
References
Abbasi, E. (2025). The impact of climate change on travel-related vector-borne diseases: A case study on dengue virus transmission. Travel Medicine and Infectious Disease, 65(March), 102841. https://doi.org/10.1016/j.tmaid.2025.102841
Agrawal. (2024). Analysis and recommendation system-based on PRISMA checklist to write systematic review. Assessing Writing, 61, 100866.
Alanazi, F. T. H., Alharbi, B. N., Aljuaid, T. H., Alammar, F. A., Almarzouq, Y. F., Albalawi, I., Almutairi, M. N., Alshaghroud, S. M., Alhaosawi, M. E., Albalawi, M. A. S., & Alorf, A. A. (2024). The impact of vaccinations on disease prevention: A comprehensive analysis of their role in enhancing global public health and reducing morbidity and mortality rates. International Journal of Health Sciences, 8(S1), 1885–1907. https://doi.org/10.53730/ijhs.v8ns1.15436
Castellano, V. E., Diana Menéndez, S., Ochoa, J., Burgos, F., Fernadez, F., Gigliotti, R., Díaz, M., & Bonvehí, P. (2025). Retrospective analysis of one year of passive safety surveillance data following implementation of the dengue vaccine, Qdenga® (TAK-003) at private vaccination centers, in Buenos Aires, Argentina. Vaccine: X, 27(November). https://doi.org/10.1016/j.jvacx.2025.100749
El Hindi, T., Anugulruengkitt, S., Lapphra, K., Limkittikul, K., Tangsathapornpong, A., Galindo-Tsoukas, C., Hellwig, M., Roubinis, N., Schuring, R., Biswal, S., & Folschweiller, N. (2025). Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine. Vaccine, 62(March), 127558. https://doi.org/10.1016/j.vaccine.2025.127558
Flacco, M. E., Bianconi, A., Cioni, G., Fiore, M., Calò, G. L., Imperiali, G., Orazi, V., Tiseo, M., Troia, A., Rosso, A., & Manzoli, L. (2024). Immunogenicity, Safety and Efficacy of the Dengue Vaccine TAK-003: A Meta-Analysis. Vaccines, 12(7), 1–13. https://doi.org/10.3390/vaccines12070770
Hou, J., Ye, W., & Chen, J. (2022). Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines. Frontiers in Immunology, 13(February), 1–13. https://doi.org/10.3389/fimmu.2022.840104
Idris. (2021). An update on dengue vaccine development, challenges, and future perspectives. Expert Opinion on Drug Discovery, 16(1), 47–58.
Jackson, L. A., Rupp, R., Papadimitriou, A., Wallace, D., Raanan, M., & Moss, K. J. (2018). A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate. Vaccine, 36(27), 3976–3983. https://doi.org/10.1016/j.vaccine.2018.05.028
Lindstrand, A., Cherian, T., Chang-Blanc, D., Feikin, D., & O’brien, K. L. (2021). The World of Immunization: Achievements, Challenges, and Strategic Vision for the Next Decade. Journal of Infectious Diseases, 224(Suppl 4), S452–S467. https://doi.org/10.1093/infdis/jiab284
López-Medina, E., Biswal, S., Saez-Llorens, X., Borja-Tabora, C., Bravo, L., Sirivichayakul, C., Vargas, L. M., Alera, M. T., Velásquez, H., Reynales, H., Rivera, L., Watanaveeradej, V., Rodriguez-Arenales, E. J., Yu, D., Espinoza, F., Dietze, R., Fernando, L. K., Wickramasinghe, P., Duarte Moreira, E., … Borkowski, A. (2022). Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination. Journal of Infectious Diseases, 225(9), 1521–1532. https://doi.org/10.1093/infdis/jiaa761
Mondelli, M. U. (2023). Does co-administration of vaccines interfere with immune responses? The jury is still out. Clinical Microbiology and Infection, 29(12), 1482–1484. https://doi.org/10.1016/j.cmi.2023.09.022
Nakhaie. (2026). Dengue Fever: Viral, Environmental, and Human Factors Driving Expansion and Pandemic Risk. Reviews in Medical Virology, 36(1), 70088.
Patel, S. S., Winkle, P., Faccin, A., Nordio, F., LeFevre, I., & Tsoukas, C. G. (2023). An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life. Human Vaccines and Immunotherapeutics, 19(2). https://doi.org/10.1080/21645515.2023.2254964
Roy, S. K., & Bhattacharjee, S. (2021). Dengue virus: Epidemiology, biology, and disease aetiology. Canadian Journal of Microbiology, 67(10), 687–702. https://doi.org/10.1139/cjm-2020-0572
Salmon, D. A., Lambert, P. H., Nohynek, H. M., Gee, J., Parashar, U. D., Tate, J. E., Wilder-Smith, A., Hartigan-Go, K. Y., Smith, P. G., & Zuber, P. L. F. (2021). Novel vaccine safety issues and areas that would benefit from further research. BMJ Global Health, 6, 1–11. https://doi.org/10.1136/bmjgh-2020-003814
Schmidt, L., Olorisade, B. K., McGuinness, L. A., Thomas, J., & Higgins, J. P. T. (2021). Data extraction methods for systematic review (semi)automation: A living systematic review. F1000Research, 10, 401. https://doi.org/10.12688/f1000research.51117.1
Shafie, A. A., Moreira, E. D., Vidal, G., Di Pasquale, A., Green, A., Tai, R., & Yoong, J. (2024). Sustainable Dengue Prevention and Management: Integrating Dengue Vaccination Strategies with Population Perspectives. Vaccines, 12(2), 1–10. https://doi.org/10.3390/vaccines12020184
Sharp. (2022). Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation. The Lancet Infectious Diseases, 22(2), 42–51.
Tricou, V., Eyre, S., Ramjee, M., Collini, P., Mojares, Z., Loeliger, E., Mandaric, S., Rauscher, M., Brose, M., Lefevre, I., Folschweiller, N., & Wallace, D. (2023). A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country. Vaccine, 41(7), 1398–1407. https://doi.org/10.1016/j.vaccine.2023.01.007
Tricou, V., Winkle, P. J., Tharenos, L. M., Rauscher, M., Escudero, I., Hoffman, E., LeFevre, I., Borkowski, A., & Wallace, D. (2023). Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults. Vaccine, 41(47), 6999–7006. https://doi.org/10.1016/j.vaccine.2023.09.049
Tricou, V., Yu, D., Reynales, H., Biswal, S., Saez-Llorens, X., Sirivichayakul, C., Lopez, P., Borja-Tabora, C., Bravo, L., Kosalaraksa, P., Vargas, L. M., Alera, M. T., Rivera, L., Watanaveeradej, V., Dietze, R., Fernando, L. K., Wickramasinghe, V. P., Moreira, E. D., Fernando, A. D., … Wallace, D. (2024). Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet Global Health, 12(2), e257–e270. https://doi.org/10.1016/S2214-109X(23)00522-3
Wilder-Smith, A., Cherian, T., & Hombach, J. (2025). Dengue Vaccine Development and Deployment into Routine Immunization. Vaccines, 13(5), 1–12. https://doi.org/10.3390/vaccines13050483
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Indonesian Health Issue
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
